Results 191 to 200 of about 33,833 (238)

Prevalence of comorbidities and their impact on prognosis among patients with rifampicin-resistant tuberculosis: a multicenter retrospective cohort study in China. [PDF]

Sci Rep
Zou L, Li Z, Pan Q, Ma J, Tang P, Kang W, Chen Q, Shi Z, Tang X, Guo C, Du J, Zhu Q, Yang S, Chang Z, Guo Z, Tang S, Wu G.   +16 more
europepmc   +1 more source

Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort. [PDF]

BMJ Open
Boois L, Ekandjo H, Shavuka O, Nepolo E, Ndong Sima CA, Oelofse C, Uren C, Petersen DC, Möller M, Wijk M, Kellermann T, Decloedt E, McIlleron H, Denti P, Claassens MM.   +14 more
europepmc   +1 more source

A Telacebec-Shaped Puzzle Piece in the Treatment of Mycobacterial Diseases. [PDF]

Am J Respir Crit Care Med
de Jong BC.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bioactives from medicinal herb against bedaquiline resistant tuberculosis: Removing the Dark Clouds from the Horizon.

Microbes and infection, 2023
Tuberculosis is a contagious bacterial ailment that primarily affects the lungs and is brought on by the bacterium Mycobacterium tuberculosis (MTB).
Rahul Singh, Souvik Manna, Hemraj Nandanwar, Rituraj Purohit   +3 more
semanticscholar   +1 more source

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

Lancet. Infectious Diseases (Print)
BACKGROUND Linezolid is a key component globally in first-line therapy for drug-resistant tuberculosis but has considerable toxicity. New and safer alternative oxazolidinones are needed. Sutezolid is one such promising alternative.
Norbert Heinrich, Christina Manyama, S. Koele, S. Mpagama, Francis Mhimbira, M. Sebe, Robert S. Wallis, N. Ntinginya, A. Liyoyo, Beno Huglin, L. Minja, Larissa Wagnerberger, Krista Stoycheva, Tresphory B. Zumba, I. Noreña, Daud D Peter, H. Makkan, D. Sloan, L. Brake, J. Schildkraut, R. Aarnoutse, Timothy D Mchugh, L. Wildner, M. Boeree, Brian H Aldana, P. Phillips, Michael Hoelscher, E. Svensson   +27 more
semanticscholar   +1 more source

Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity

Proceedings of the National Academy of Sciences of the United States of America
Significance Bedaquiline, an antitubercular drug targeting ATP synthase, forms the backbone of highly efficacious treatment regimens for drug-resistant tuberculosis.
Adam J. Fountain, Natalie J. E. Waller, Chen-Yi Cheung, William J. Jowsey, Michael T Chrisp, Mark Troll, P. H. Edelstein, Gregory M. Cook, Matthew B. McNeil, Lalita Ramakrishnan   +9 more
semanticscholar   +1 more source